Related Experiment Video

Updated: May 8, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Increasing awareness of hypoglycaemia in patients with type 2 diabetes treated with oral agents

A H Barnett1, R Brice, W Hanif

  • 1Diabetes Centre, Heart of England NHS foundation Trust and University of Birmingham , Birmingham , UK.

Current Medical Research and Opinion
|August 20, 2013
PubMed

Insights

Hypoglycaemia, a common complication of type 2 diabetes, significantly impacts patients and healthcare. Prevention strategies include education, self-monitoring, and individualized therapy to mitigate risks associated with diabetes medications.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Hypoglycaemia is the most frequent acute complication in type 2 diabetes (T2D).
  • It is a significant side effect of common T2D medications like insulin and insulin secretagogues.
  • Patients often underreport hypoglycaemic events, despite their substantial impact.

Purpose of the Study:

  • To enhance understanding of hypoglycaemia's impact and consequences in T2D.
  • To specifically examine hypoglycaemia associated with sulphonylurea therapy.
  • To identify areas for improved management of T2D.

Main Methods:

  • This is a review article.
  • It synthesizes existing literature on hypoglycaemia in T2D.
  • Focuses on clinical practice, patient impact, and therapeutic strategies.

Main Results:

  • Hypoglycaemia negatively affects treatment satisfaction, adherence, quality of life, and leads to serious health consequences.
  • Previous hypoglycaemia is the primary risk factor for future events.
  • Effective prevention requires patient education, self-monitoring, awareness of triggers, and tailored glycemic targets.

Conclusions:

  • Addressing hypoglycaemia is crucial for effective T2D management.
  • Individualized therapeutic approaches and patient education are key to prevention.
  • Further attention is needed to mitigate the burden of hypoglycaemia in T2D patients.

Related Concept Videos

Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...